One limitation of Digibind is its cost, which can be prohibitive in some healthcare settings. Additionally, it may not be effective in cases of chronic digoxin toxicity, where tissue levels are high but serum levels appear normal. In such cases, Digibind may not completely reverse toxicity. Moreover, patients with renal impairment may experience delayed elimination of the digoxin-antibody complex, requiring careful dose adjustment and monitoring.
